Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. (Nasdaq AVR) has filed a PRE 14A calling a fully virtual special meeting for 4 Sep 2025.
Shareholders will vote on: (1) ASX’s three-year waiver of Listing Rule 7.1, allowing equity issuances above the current 15 % cap without prior ASX shareholder approval, and (2) authority to adjourn the meeting to gather more proxies if Proposal 1 lacks support.
The board argues the waiver aligns AVR with U.S. peers and provides funding flexibility for the DurAVR THV program, while Nasdaq’s 20 % and change-of-control rules will still govern large deals.
Proposal 1 needs 75 % of votes cast; Proposal 2 needs a simple majority. Illustrative scenarios show potential shareholder dilution from 8 % up to 73 %, depending on deal size and price. Record date is 11 Aug 2025; CDI holders must instruct CDN to vote on their behalf.
The board unanimously recommends voting FOR both proposals.